cabozantinib

Details

Files

Generic Name:

cabozantinib

Project Status:

Pending

Therapeutic Area:

Neuroendocrine tumours

Manufacturer:

N/A

Call for patient/clinician input open:

January 9, 2025

Brand Name:

N/A

Project Line:

Reimbursement Review

Project Number:

PX0378-000

Call for patient/clinician input closed:

March 3, 2025

Biosimilar:

Submission Type:

Non-sponsored Submission

Fee Schedule:

Pending

Indications:

For the treatment of locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (nPNET).

Anticipated Date:

December 12, 2024

Last Updated : January 9, 2025